Binance CEO Zhao Changpeng warned that AI could harm the crypto space by intensifying phishing and social engineering attacks through leaked data, without actually breaking Bitcoin's cryptography. He highlighted that internet and banking systems use weaker cryptography, making them more vulnerable. This concern aligns with earlier warnings about AI-assisted discovery of software flaws in wallets, where experts say software weaknesses pose a more immediate security threat than AI cracking Bitcoin's cryptography.
The discussion on AI's impact on crypto security provides context for Pluang's cryptocurrency market data. For readers following crypto, here is Pluang's market snapshot as of Oct 24, 2026 01:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 43 rose and 6 fell today. Notable movers include LUNC (Terra Classic) at Rp0,841 with a 3.57% increase and a buy order activity of 76%, YFI (Yearn) priced at Rp39.837.602 up 3.00% with 67% buy orders, and UNI (Uniswap) at Rp129.204 rising 2.60% with a slight majority of sell orders at 52%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
